Latest Chemoradiotherapy Stories
CAMBRIDGE, Mass., March 18, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2 trial designed to (1) identify the recommended Phase 2 dose of CRLX101 in combination with Xeloda(®) (capecitabine) and radiation (chemoradiotherapy) and (2) detect signals, if any, of increased efficacy over standard neoadjuvant chemoradiotherapy for rectal cancer. The trial is...
- An evil spirit; a devil.
- A nightmare.
- In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.